Publications by authors named "C Cenjor Espanol"
Article Synopsis
- The ATLAS-2M study evaluated the effectiveness and safety of cabotegravir (CAB) + rilpivirine (RPV) for maintaining HIV-1 suppression, comparing two dosing schedules: every 8 weeks (Q8W) and every 4 weeks (Q4W).
- Results showed that both dosing regimens were effective, with 87% of participants maintaining low HIV-1 levels after 152 weeks, and Q8W dosing was confirmed to be noninferior to Q4W.
- The study found that safety profiles were similar for both groups, with no new safety concerns, confirming CAB + RPV as a long-term treatment option for HIV-1 suppression.
Article Synopsis
- - Cabotegravir + rilpivirine is a new long-acting antiretroviral therapy given monthly or every two months, but the COVID-19 pandemic disrupted many patients' clinic visits for injections.
- - A study evaluated how well the treatment was maintained during the pandemic across various clinical trials, finding that 94% of participants continued their planned dosing without major issues despite some visits being affected.
- - Most of the 130 affected participants switched to oral therapy to ensure continued treatment, with 98% maintaining effective viral suppression, highlighting the flexibility of the treatment approach during the pandemic.
Most public health measures to contain the COVID-19 pandemic are based on preventing the pathogen spread, and the use of oral antiseptics has been proposed as a strategy to reduce transmission risk. The aim of this manuscript is to test the efficacy of mouthwashes to reduce salivary viral load in vivo. This is a multi-centre, blinded, parallel-group, placebo-controlled randomised clinical trial that tests the effect of four mouthwashes (cetylpyridinium chloride, chlorhexidine, povidone-iodine and hydrogen peroxide) in SARS-CoV-2 salivary load measured by qPCR at baseline and 30, 60 and 120 min after the mouthrinse.
View Article and Find Full Text PDFBackground: Long-acting cabotegravir and rilpivirine administered monthly or every 2 months might address the challenges associated with daily oral antiretroviral therapy. The ATLAS-2M week 48 results showed non-inferiority of long-acting cabotegravir and rilpivirine administered every 8 weeks compared with that of every 4 weeks. In this study, we report the efficacy, safety, and tolerability results from the week 96 analysis.
View Article and Find Full Text PDFObjectives: Head and neck surgery is associated with a steep learning curve, creating a need for effective training methods. Live animal models can be useful in acquiring the required skills and techniques to perform tracheostomy, neck dissection, and laryngectomy. The aim of this study is to assess the feasibility and usefulness of a porcine model to teach tracheostomy, neck dissection, and laryngectomy, describing the similarities between a swine head and neck surgical model and the human cervical area.
View Article and Find Full Text PDF